In-Vitro ADME Testing Services Market, 2030: Services, Assays, Molecule(s), Type of Sponsor Company, Therapeutic Areas
DUBLIN, Dec. 3, 2019 /PRNewswire/ -- The "In Vitro ADME Testing Services Market, 2019-2030" report has been added to ResearchAndMarkets.com's offering.
https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg
The In Vitro ADME Testing Services Market, 2019-2030' report features a comprehensive study of the current landscape of in vitro ADME testing service providers.
The study presents an in-depth analysis, highlighting the capabilities of various stakeholders across different global regions.
One of the key objectives of the report is to evaluate the current opportunity and the future potential of the in vitro ADME testing services market over the coming decade. We have provided an informed estimate of the likely evolution of the market in the short to mid-term and long term, for the period 2019-2030.
In addition, we have segmented the future opportunity across [A] different global regions (North America, Europe, Asia-Pacific and rest of the world), [B] type of services (absorption, distribution, metabolism and excretion), [C] type of assays (across 5+ categories), [D] type of molecule(s) (biologics and small molecules), [E] type of sponsor company (pharmaceutical / biotechnology companies and academic / research institutes) and [F] therapeutic areas (across 10+ categories).
To account for the uncertainties associated with the in vitro ADME testing services market and to add robustness to our model, we have provided three forecast scenarios, portraying the conservative, base and optimistic tracks of the market's evolution.
Amongst other elements, the report includes:
-- A detailed assessment of the current market landscape, featuring a
comprehensive list of over 90 CROs that offer in vitro ADME testing
services, and analyses based on a number of parameters, such as year of
establishment, headquarter location(s), company size, type of additional
service(s) offered (in vivo ADME, in silico ADME and toxicology
testing), range of assays offered within in vitro ADME service portfolio
(blood to plasma ratio, Caco-2 permeability, cytochrome (CYP) enzyme
induction / inhibition, metabolic stability, plasma protein binding,
reaction phenotyping and others), type of molecule(s) (biologics and
small molecules), and type of clientele (pharmaceutical / biotechnology
companies and academic / research institutes).
-- A schematic logo landscape of in vitro ADME service providers,
highlighting their geographical distribution (on the basis of location
of headquarters) and company size (small-sized (1-50 employees),
mid-sized (51-200 employees), large (201-1,000 employees), and very
large (>1,000 employees)).
-- A discussion on the various outsourcing business models adopted in this
domain, along with a list of key considerations that need to be taken
into account by industry stakeholders while selecting a CRO partner.
-- Elaborate profiles of popular in vitro ADME testing service providers,
featuring a brief overview of the company, its financial information (if
available), information on in vitro ADME service(s) capabilities, and a
comprehensive future outlook.
-- A comprehensive benchmark analysis, highlighting the key focus areas of
small, mid-sized and large companies, comparing their existing
capabilities within and beyond their respective peer groups, and
thereby, providing a means for stakeholders to identify ways to gain a
competitive edge in the industry.
-- A detailed analysis of the various mergers and acquisitions that have
taken place in this domain, highlighting the trend in the number of
companies acquired between 2005-2018, along with the geographical
distribution of this activity. The analysis also features an ownership
change matrix, providing a summary of the involvement of private and
public sector entities in this domain.
-- A detailed discussion on the various regulatory guidelines related to in
vitro ADME testing, which have been laid down by major international /
regional regulatory bodies (namely European Medicine Agency (EMA), US
Food and Drug Administration (USFDA), Ministry of Health, Labor and
Welfare (MHLW), International Council for Harmonisation (ICH) of
Technical Requirements for Pharmaceuticals for Human Use, the
Organisation for Economic Co-operation and Development (OECD), and World
Health Organization (WHO)).
Chapter Outlines
-- Chapter 2 provides an executive summary of the insights captured in our
research. It offers a high-level view on the current scenario within the
in vitro ADME testing services market and its likely evolution in the
short-mid and long term.
-- Chapter 3 provides an introduction to the overall drug discovery
process, with details on the time taken for a drug to traverse through
the various stages of drug development and into the market. It includes
an overview of ADME testing, featuring a detailed discussion on the
significance of evaluating various ADME parameters within the drug
discovery and development process. Further, the chapter presents
insights on the benefits of carrying out ADME testing at early stages of
drug development. It also features details related to various contract
services that can be availed by industry stakeholders seeking to
outsource ADME testing.
-- Chapter 4 features a detailed discussion on the various outsourcing
related business models that are commonly adopted by the industry
stakeholders in relation to ADME testing. The chapter includes a list of
factors that drive sponsors to outsource their ADME testing operations.
It also highlights several key parameters that sponsors need to take
into consideration while choosing a CRO partner. The chapter features an
elaborate discussion on the benefits of outsourcing ADME services, along
with the affiliated risks and challenges.
-- Chapter 5 provides a comprehensive view on the global landscape of in
vitro ADME testing service providers. It includes information related to
over 90 CROs that claim to offer in vitro ADME services, featuring
in-depth analyses of the players based on their year of establishment,
headquarter location(s), company size, type of additional service(s)
offered, range of assays offered within in vitro ADME service portfolio,
type of molecule(s), and type of clientele. The chapter also includes a
list of 70 players offering in silico ADME services. In addition, it
also features a logo landscape of the players that claim to offer in
vitro ADME services, distributed on the basis of the location of their
respective headquarters and company size.
-- Chapter 6 features detailed profiles of key CROs that claim to offer in
vitro ADME testing services, across different geographies. Each company
profile includes a brief overview of the company, financial information
(if available), information on in vitro ADME service(s) capabilities,
and a comprehensive future outlook.
-- Chapter 7 presents a benchmark analysis of the various players engaged
in this domain. It highlights the capabilities of the companies in terms
of their expertise across various services related to in vitro ADME
testing. The analysis allows companies to compare their existing
capabilities within and beyond their respective peer groups, and
thereby, providing a means for stakeholders to identify ways to gain a
competitive edge in the industry.
-- Chapter 8 features a detailed analysis of the mergers and acquisitions
that have taken place in this space, highlighting the trend in the
number of companies acquired from 2005 to 2018. The analysis also
features an ownership change matrix, providing a summary of the
involvement of private and public sector entities in this domain.
-- Chapter 9 features information on the regulatory guidelines that have
been laid down by key regulatory bodies/organizations, specific to ADME
testing in the pharmaceutical industry. These are EMA, ICH, MHLW, OECD,
USFDA and WHO.
-- Chapter 10 features a comprehensive market forecast, highlighting the
future potential of in vitro ADME testing services market till 2030. The
projected opportunity has been further analyzed to develop a better
perspective related to its distribution across [A] different global
regions (North America, Europe, Asia-Pacific and rest of the world), [B]
type of services (absorption, distribution, metabolism and excretion),
[C] type of assays (across 5+ categories), [D] type of molecule(s)
(biologics and small molecules), [E] type of sponsor company
(pharmaceutical / biotechnology companies and academic / research
institutes) and [F] therapeutic areas (across 10+ categories).
-- Chapter 11 summarizes the entire report. It presents a list of key
takeaways and offers our independent opinion on the current market
scenario. Further, it captures the evolutionary trends that are likely
to determine the future of this segment of the biopharmaceutical
industry.
-- Chapter 12 is a collection of interview transcripts of the discussions
that were held with key stakeholders in this market. In this chapter, we
have presented the details of interviews held with Dan Close (Chief
Scientific Officer, 490 BioTech), and Sridhar Iyer (Director and Global
Head, Business Development, JRF Global) and Sarang Gorte (Assistant
Manager, Business Development, JRF Global).
-- Chapter 13 is an appendix, which provides tabulated data and numbers for
all the figures provided in the report.
-- Chapter 14 is an appendix, which contains the list of companies and
organizations mentioned in the report.
For more information about this report visit https://www.researchandmarkets.com/r/miy1ps
Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.
Media Contact:
Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
View original content:http://www.prnewswire.com/news-releases/in-vitro-adme-testing-services-market-2030-services-assays-molecules-type-of-sponsor-company-therapeutic-areas-300968150.html
SOURCE Research and Markets
